- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular pathology of lung cancer: key to personalized medicine
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume 25, Issue 3, Pages 347-369
Publisher
Springer Nature
Online
2012-01-28
DOI
10.1038/modpathol.2011.215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Non–Small Cell Lung Cancer
- (2017) David S. Ettinger et al. Journal of the National Comprehensive Cancer Network
- EGFR-mutated lung cancer: a paradigm of molecular oncology
- (2015) Oncotarget
- Adenosquamous Carcinoma of the Lung
- (2011) Naobumi Tochigi et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
- (2011) T. Sasaki et al. CANCER RESEARCH
- Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors
- (2011) J. Qi et al. CANCER RESEARCH
- Targeting Anaplastic Lymphoma Kinase in Lung Cancer
- (2011) A. T. Shaw et al. CLINICAL CANCER RESEARCH
- Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
- (2011) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
- (2011) Rebekka Krumbach et al. EUROPEAN JOURNAL OF CANCER
- The landscape ofEGFRpathways and personalized management of non-small-cell lung cancer
- (2011) Liang Cheng et al. Future Oncology
- Large-Cell Neuroendocrine Carcinoma of the Lung Harboring EGFR Mutation and Responding to Gefitinib
- (2011) Tommaso M. De Pas et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
- (2011) Yasushi Yatabe et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations
- (2011) Paul K. Paik et al. JOURNAL OF CLINICAL ONCOLOGY
- Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
- (2011) Qing Zhou et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
- (2011) Vicki Leigh Keedy et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice
- (2011) Leina Sun et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
- (2011) Kenneth J O'Byrne et al. LANCET ONCOLOGY
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- (2011) Alice T Shaw et al. LANCET ONCOLOGY
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- New driver mutations in non-small-cell lung cancer
- (2011) William Pao et al. LANCET ONCOLOGY
- Tubuline, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum–gemcitabine chemotherapy
- (2011) M. Joerger et al. LUNG CANCER
- Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
- (2011) F. Janku et al. Nature Reviews Clinical Oncology
- The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models
- (2011) E Normant et al. ONCOGENE
- Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR
- (2011) Ronald van Eijk et al. PLoS One
- Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR
- (2011) George Santis et al. PLoS One
- Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
- (2011) R. Katayama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- (2011) Peter S. Hammerman et al. Cancer Discovery
- Correlation of genes associated with drug response to prognosis of large cell lung carcinoma
- (2011) Cheng Chen et al. Chinese Journal of Cancer
- Visualization of FISH Probes by Dual-Color Chromogenic In Situ Hybridization
- (2010) Kirsten Hoff et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry
- (2010) Lynette M. Sholl et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Discovery of selective irreversible inhibitors for EGFR-T790M
- (2010) Wenjun Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- Acquired Resistance of Non-Small Cell Lung Cancer Cells to MET Kinase Inhibition Is Mediated by a Switch to Epidermal Growth Factor Receptor Dependency
- (2010) U. McDermott et al. CANCER RESEARCH
- MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies forKRASMutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
- (2010) Juyong Yoon et al. CANCER RESEARCH
- Role of Survivin in EGFR Inhibitor-Induced Apoptosis in Non-Small Cell Lung Cancers Positive for EGFR Mutations
- (2010) K. Okamoto et al. CANCER RESEARCH
- Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy
- (2010) Hongbin Ji CANCER SCIENCE
- Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
- (2010) David Paez et al. CANCER SCIENCE
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
- (2010) K. Suda et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
- (2010) Geoffrey R. Oxnard et al. CLINICAL CANCER RESEARCH
- A Review of Epidermal Growth Factor Receptor/HER2 Inhibitors in the Treatment of Patients With Non–Small-Cell Lung Cancer
- (2010) Ramaswamy Govindan Clinical Lung Cancer
- Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies
- (2010) Sarah Barton et al. CURRENT CANCER DRUG TARGETS
- The biology and treatment of EML4-ALK non-small cell lung cancer
- (2010) Takaaki Sasaki et al. EUROPEAN JOURNAL OF CANCER
- A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond
- (2010) Martin Reck Expert Review of Anticancer Therapy
- Clinical implications ofMETgene copy number in lung cancer
- (2010) Luca Toschi et al. Future Oncology
- Personalized Medicine in Non–Small-Cell Lung Cancer: IsKRASa Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?
- (2010) Patrick J. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer
- (2010) Shirin Khambata-Ford et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR
- (2010) Marie Brevet et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- KRAS and BRAF: drug targets and predictive biomarkers
- (2010) Efsevia Vakiani et al. JOURNAL OF PATHOLOGY
- ALK, Lung Cancer, and Personalized Therapy: Portent of the Future?
- (2010) Ken Garber JNCI-Journal of the National Cancer Institute
- Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer
- (2010) David R. Gandara et al. Journal of Thoracic Oncology
- Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans
- (2010) J. Matthew Reinersman et al. Journal of Thoracic Oncology
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
- (2010) Roy S Herbst et al. LANCET ONCOLOGY
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Recurrent EML4–ALK-associated lung adenocarcinoma with a slow clinical course
- (2010) Shuji Murakami et al. LUNG CANCER
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations
- (2010) M. Tiseo et al. LUNG CANCER
- Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
- (2010) Xuchao Zhang et al. Molecular Cancer
- Cancer-Associated Fibroblasts Derived from EGFR-TKI-Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
- (2010) S. R. Mink et al. MOLECULAR CANCER RESEARCH
- KRASmutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
- (2010) Young-Kwang Yoon et al. MOLECULAR CARCINOGENESIS
- Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
- (2010) Mallika Singh et al. NATURE BIOTECHNOLOGY
- The molecular pathology of cancer
- (2010) Timothy J. R. Harris et al. Nature Reviews Clinical Oncology
- Understanding resistance to EGFR inhibitors—impact on future treatment strategies
- (2010) Deric L. Wheeler et al. Nature Reviews Clinical Oncology
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
- (2010) Young Lim Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation
- (2010) I. Vivanco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGFR mutation detection in NSCLC—assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
- (2010) Roland Penzel et al. VIRCHOWS ARCHIV
- Micropapillary Lung Adenocarcinoma
- (2009) Rosane De Oliveira Duarte Achcar et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues
- (2009) Maria Paola Martelli et al. AMERICAN JOURNAL OF PATHOLOGY
- Anaplastic lymphoma kinase: signalling in development and disease
- (2009) Ruth H. Palmer et al. BIOCHEMICAL JOURNAL
- TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS
- (2009) Daisy Wing-Sze Wong et al. CANCER
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2009) I. J. Dahabreh et al. CLINICAL CANCER RESEARCH
- Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2009) P. S. Hammerman et al. CLINICAL CANCER RESEARCH
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor Inhibitors and Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer
- (2009) L. Horn et al. CLINICAL CANCER RESEARCH
- Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
- (2009) D. M. Jackman et al. CLINICAL CANCER RESEARCH
- EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
- (2009) K. Schmid et al. CLINICAL CANCER RESEARCH
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
- (2009) J. P. Eder et al. CLINICAL CANCER RESEARCH
- KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer
- (2009) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer
- (2009) J. Yu et al. CLINICAL CANCER RESEARCH
- Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
- (2009) S. J. Rodig et al. CLINICAL CANCER RESEARCH
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Mechanisms of tumor resistance to EGFR-targeted therapies
- (2009) Elizabeth A Hopper-Borge et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
- (2009) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
- (2009) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
- (2009) David Jackman et al. JOURNAL OF CLINICAL ONCOLOGY
- Evidence for Common Clonal Origin of Multifocal Lung Cancers
- (2009) Xiaoyan Wang et al. JNCI-Journal of the National Cancer Institute
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- (2009) Salvatore Siena et al. JNCI-Journal of the National Cancer Institute
- MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort
- (2009) Michèle Beau-Faller et al. Journal of Thoracic Oncology
- Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites
- (2009) Carlos Gomez-Roca et al. Journal of Thoracic Oncology
- Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer
- (2009) Howard West et al. Journal of Thoracic Oncology
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies
- (2009) Chen Mao et al. LUNG CANCER
- EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology and young onset
- (2009) Kentaro Inamura et al. MODERN PATHOLOGY
- Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations
- (2009) I. Y.-S. Tam et al. MOLECULAR CANCER THERAPEUTICS
- Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
- (2009) Helena Linardou et al. Nature Reviews Clinical Oncology
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
- (2009) A F Gazdar ONCOGENE
- The Histopathology of BRAF-V600E–mutated Lung Adenocarcinoma
- (2008) Samuel A. Yousem et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
- (2008) K Tamura et al. BRITISH JOURNAL OF CANCER
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
- (2008) C Lemos et al. BRITISH JOURNAL OF CANCER
- Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors
- (2008) U. McDermott et al. CANCER RESEARCH
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer
- (2008) Y. L. Choi et al. CANCER RESEARCH
- Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
- (2008) K. Takeuchi et al. CLINICAL CANCER RESEARCH
- Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non-Small Cell Lung Cancer
- (2008) T. Fukui et al. CLINICAL CANCER RESEARCH
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib
- (2008) D. B. Costa et al. CLINICAL CANCER RESEARCH
- Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
- (2008) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma
- (2008) Naoki Hijiya et al. HUMAN PATHOLOGY
- Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
- (2008) Amit Kumar et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- IncreasedEGFRGene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
- (2008) Fred R. Hirsch et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting
- (2008) David A. Eberhard et al. JOURNAL OF CLINICAL ONCOLOGY
- Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy
- (2008) Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR Mutations in Lung Adenocarcinomas
- (2008) Allan R. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers
- (2008) Kentaro Inamura et al. Journal of Thoracic Oncology
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Impact of EGFR mutation analysis in non-small cell lung cancer
- (2008) Hiromasa Yamamoto et al. LUNG CANCER
- Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation
- (2008) Hideki Endoh et al. LUNG CANCER
- Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma
- (2008) Xiaoyan Wang et al. MODERN PATHOLOGY
- Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
- (2008) Marc Ladanyi et al. MODERN PATHOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- EGFR Antagonists in Cancer Treatment
- (2008) Fortunato Ciardiello et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Mutations inEGFRin Circulating Lung-Cancer Cells
- (2008) Shyamala Maheswaran et al. NEW ENGLAND JOURNAL OF MEDICINE
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: A fluorescence in situ hybridization and immunohistochemical analysis
- (2008) Rebecca A. Marks et al. PROSTATE
- ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer
- (2007) Kyung-Hun Lee et al. LUNG CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started